Press Releases

Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch

17th May 2022

– Emergex’s COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials Abingdon, Oxon, UK, 17th May 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its […]

Emergex Provides an Update on First-in-Human Studies of Its Novel Dengue Fever and Coronavirus T cell Adaptive Vaccines

18th April 2022

– Both studies fully recruited, with data from the Dengue Fever study anticipated in the summer – Preclinical data for Emergex’s Coronavirus vaccine candidate suggests that it could provide heterologous immunity to viruses from the same family Abingdon, Oxon, UK, 18 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage […]

Emergex Advances Vaccine Candidate for Tularemia, Highlighting the Potential of T cell Priming Vaccines in National Preparedness Initiatives

14th April 2022

· Emergex’s CD8+ T cell Adaptive Vaccine platform will now be used to generate a tularemia vaccine candidate that provides a cytotoxic (killing of infected cells) CD8+ T cell response and offers a means for rapid development suitable for deployment as a medical countermeasure. · Emergex’s ongoing Phase I clinical trials on vaccine candidates for […]

Emergex Signs Agreement with ATCC to Advance Studies of its Yellow Fever Booster Vaccine Candidate

7th April 2022

Abingdon, Oxon, UK, 7 April 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a company addressing major global infectious disease threats through the development of fully synthetic CD8+ T-Cell Adaptive Vaccines, today announces that it has entered into an agreement with ATCC to progress preclinical development of its Yellow Fever booster vaccine program. […]

Emergex Awarded £490,525 UK Aid Grant by the Department of Health and Social Care to Advance Synthetic T cell Vaccine Candidate for Chikungunya Virus

22nd February 2022

Abingdon, Oxon, UK, 22 February 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic Priming T cell Adaptive Vaccines, today announces that it has been awarded a £490,525 grant by the UK government’s Department of Health and Social Care (‘DHSC’) […]

Emergex confirms its next generation T-Cell Priming COVID-19 vaccine candidate has the potential to be effective against all currently sequenced viral mutations

1st December 2021

Emergex confirms that the viral peptides in its COVID-19 vaccine candidate are present in the following sequenced variants, including B.1.1.7(Alpha, UK), B.1.1.28 (Gamma, Brazil) B.1.351 (Beta, South Africa), B.1.429 (South Carolina) B.1.617.2 (Delta, India), B.1.1.529 (Omicron, multiple countries) – meaning that no impact on the efficacy of the vaccine is anticipated Emergex’s COVID-19 vaccine uses […]

Emergex announces approval to initiate Phase I clinical trial of its next generation COVID-19 vaccine candidate

15th November 2021

Synthetic vaccine designed to prime T-Cells to rapidly remove viral-infected cells from the body after infection May offer broad immunity against SARS-CoV-1 and all SARS-CoV-2 variants and provide long-lasting immunity that does not require seasonal booster vaccines Abingdon, Oxon, UK, 15 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling […]

Next-generation COVID-19 vaccines – looking beyond spike protein and SARS-CoV-1 variants

15th November 2021

The response to COVID-19 – a success story in vaccine development The accelerated development of vaccines against COVID-19 and their deployment in mass vaccination programmes has been a major public health achievement. The landscape of vaccine development has undergone rapid change in the global response to the pandemic, with the utilization of novel platforms to […]

Nature paper provides further evidence of the benefits of eliciting a T-Cell response for COVID-19

11th November 2021

Abingdon, Oxon, UK, 11 November 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of 100% synthetic T Cell priming vaccines was pleased to read an interesting Nature paper published online yesterday, highlighting the role of T-Cells in some COVID-19 patients, providing rapid […]

Can One Vaccine Provide Immune Protection Against Multiple Pathogens?

27th July 2021

Can One Vaccine Provide Immune Protection Against Multiple Pathogens? The idea of one vaccine offering a wide range of protection against multiple pathogens or strains is an attractive concept – it would reduce the demands on healthcare systems to deliver vaccination programmes, provide improved uptake of vaccines and reduce the burden for patients who may […]

T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why…

27th July 2021

T-cell priming vaccines offer the potential to provide faster, broader and longer lasting immunity to reduce serious illness associated with infectious diseases such as COVID-19. Here’s why… The human immune system has evolved over millennia and includes a multitude of different immune effector cells, antibodies and signalling molecules. As our knowledge of this complex system […]

Emergex Receives Regulatory Approval for a Phase I Clinical Trial in Dengue of a T-Cell Priming Vaccine

30th June 2021

Swiss regulatory authorities, including the Swiss Agency for Therapeutic Products (Swissmedic) have granted approval for a Phase I clinical trial of Emergex’s Dengue vaccine candidate The Phase I clinical trial will evaluate the safety and look for markers of T-Cell immune response in healthy volunteers Abingdon, Oxon, UK, 30 June 2021 – Emergex Vaccines Holding […]

Emergex Appoints Dr. Anthony Sedgwick as Non-Executive Director

17th June 2021

Abingdon, Oxon, UK, 17 June 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, is pleased to announce that Dr. Anthony Sedgwick has been appointed to the Company’s Board as a Non-Executive […]

Emergex Strengthens Senior Management Team

23rd February 2021

Appointments of Mr Robin Cohen as Business Development Director and Ms Susi Osborne as Manufacturing Director Abingdon, Oxon, UK, 23 February 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development of synthetic ‘set point’ vaccines which prime the T-Cell immune response, today announces […]

Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections

28th January 2021

Emergex Notes U.S. Government Reports Highlighting the Importance of T-Cell Immunity in Controlling Viral Infections U.S. federal appropriations reports encourage support for T-Cell vaccine approaches for pandemic influenza during the 2021 fiscal year Abingdon, Oxon, UK, 28 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease […]

Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine

5th January 2021

Bio-Manguinhos, is a world leader in vaccine development and manufacturing and one of the productive units of Fiocruz, one of the world’s most respected public health research institutions Abingdon, Oxon, UK, 5 January 2021 – Emergex Vaccines Holding Limited (‘Emergex’, or ‘the Company’), a company tackling major global infectious disease threats through the development […]

Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases

18th November 2020

Investor support further endorsement of vaccine development strategy Novel approach to vaccine development could address urgent global need for safe, effective vaccines that can be rapidly developed and deployed Abingdon, Oxon, UK, 18 November 2020 – Emergex Vaccines Holding Limited (‘Emergex’), a company tackling major global infectious disease threats through the development of synthetic ‘set […]

Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells

15th September 2020

First detailed, empirical analysis of Class 1 epitopes presented by SARS-Cov-2 infected cells which define the T-Cell repertoire necessary for cytotoxic T-Cell function MHC expression library provides an accurate basis for COVID-19 T-Cell vaccine and related diagnostics development Doylestown PA, USA and Abingdon, Oxon, UK, 15 September 2020– Emergex Vaccines Holding Limited (‘Emergex’), a company […]

Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProNano

1st September 2020

Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary Emergex uniquely develops novel 100% synthetic ‘set-point’ T cell priming vaccines to address some of the world’s most pathogenic infectious diseases Current COVID-19 pandemic and ongoing threat of pandemic flu demonstrate urgent global need for safe, effective vaccines which can […]

Emergex and Bio-Manguinhos/Fiocruz Elucidate T Cell Epitopes Produced by Commercial Yellow Fever Vaccine

19th August 2020

First identification of epitopes which shape CD8 T cell response to commercial live attenuated vaccine has implications across RNA virus vaccine development Vaccine primes immune system against T cell epitopes that would be minor or subdominant in a natural infection and are derived from internal proteins Abingdon, UK and Rio de Janeiro, Brazil, 19 August […]

Emergex Signs Agreement with George Mason University for Highly Pathogenic RNA Virus Studies

22nd April 2020

Emergex Vaccines and George Mason University’s (Mason) National Center for Biodefense and Infectious Diseases (NCBID) enter into an agreement relating to the development of CD8+ priming RNA virus vaccines In particular, NCBID researchers will partner to provide additional expertise, resources, and vital samples to complement Emergex’s existing vaccine programs, including for SARS-CoV-2 Abingdon, UK, 22 […]

Publication of Coronavirus White Papers

20th April 2020

Emergex publishes three White Papers highlighting the case for developing set-point vaccines to create a universal coronavirus vaccine

Emergex Raises More Than US$11 million in a Series A Round to Progress its Pipeline of Set-point Vaccines for Infectious Diseases

9th January 2020

Emergex develops set-point vaccines to prevent some of the world’s most immediate and virulent diseases such as Zika, Dengue Fever, Ebola and pandemic Flu Vickers Venture Partners led the fundraising and Dr Finian Tan, Chairman of Vickers Venture Partners joins Emergex’s Board of Directors Capital supports pipeline developments, including progressing its first-in-man Flavivirus (Dengue) vaccine […]

Emergex Completes First Step in the Development of a Vaccine Candidate Against Intracellular Bacterium and Bioterrorist Agent Francisella Tularensis

12th December 2019

Emergex today announced it has successfully completed the first step in the development of a candidate vaccine for the Gram-negative intracellular coccobacillus, Francisella tularensis.

Emergex Successfully Completes Preclinical Testing of its Lead Set-Point Vaccine Candidate for Dengue Fever and Other Flaviviruses

10th December 2019

Emergex today announced the successful completion of preclinical testing of its lead vaccine candidate for Dengue Fever.

Emergex Signs an R&D Agreement with IMCB to Develop a Vaccine for the Emerging Threat of Hand, Foot & Mouth Disease

27th June 2019

Emergex today announced that it has signed an R&D agreement with the Institute of Molecular and Cell Biology (IMCB) in Singapore to develop a fully synthetic vaccine against human viruses that cause Hand, Foot and Mouth Disease (HFMD). Emergex and IMCB will collaborate closely to develop the new vaccine, combining their personnel, specialist knowledge and expertise.

Dr. Athanasios Papadopoulos Joins Emergex as Chief Medical Officer

27th February 2019

Emergex today announces the appointment of Athanasios Papadopoulos, MD, as Chief Medical Officer (CMO), effective 1st March 2019. Dr. Papadopoulos will report directly to Emergex’s CEO Professor Thomas Rademacher.

Emergex Secures State-of-the-art R&D Facility and Hires a Chief Scientific Officer to Drive Development of its Vaccines

18th February 2019

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a novel approach to the development of vaccines for infectious diseases, today announces that it has successfully secured a state-of-the-art-research and development (R&D) facility at Milton Park, Oxfordshire.

Emergex Demonstrates Excellent Safety Profile for Gold Nanoparticle Used in its Vaccine Platform

24th October 2018

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces the successful completion of preclinical toxicology testing on the gold nanoparticle carrier system that forms the fundamental basis for Emergex’s entire infectious disease vaccine platform.

Emergex Enters into MoU with Brazil’s Fiocruz to Develop Novel Vaccines Against Viral Diseases

20th September 2018

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to synthetic vaccine development in the field of infectious diseases, today announces that it has signed a Memorandum of Understanding (MoU) with Brazil-based Oswaldo Cruz Foundation ‘Fiocruz’ for the development of viral vaccines. The MoU initially covers the development of a vaccine that universally targets diseases within the flavivirus family such as Dengue Fever, Zika and Yellow Fever but could be expanded to include the development of vaccines to target other viral families that are endemic to the region.

Emergex Appoints US Federal Government Experts The Conafay Group

13th July 2018

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has appointed The Conafay Group, US Federal Government experts, to advise on the US healthcare landscape and policy and to provide introductions to help establish new business contacts.

Emergex Files a Patent in the USA for its Novel Pandemic Flu Vaccine

24th May 2018

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to enable synthetic vaccine development in the field of infectious diseases, today announces that it has filed a patent in the USA for its novel pandemic flu vaccine.

Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu Vaccine

14th May 2018

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

Sir David King Joins Emergex’s Board of Directors

29th March 2018

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that Sir David King has joined Emergex’s Board as a Non-Executive Director.

Emergex Builds its Finance Team with Two New Recruits

28th March 2018

Emergex Vaccines Holding Limited (‘Emergex’), a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today announces that it has built its Finance team and strengthening its operational capabilities.

Emergex Progresses its Synthetic Vaccine Development Pipeline

26th March 2018

Emergex Vaccines Holding Limited (“Emergex”), a private biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, today provides an update on its vaccine development pipeline and business.

Emergex Vaccines Awarded SBRI Contract by Innovate UK

5th April 2017

Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that they have been awarded a £499,825 SBRI contract with the Department of Health/Technology Strategy Board, facilitated by Innovate UK, the UK’s Innovation Agency. The ‘Vaccines for Global Development – Preclinical’ grant proceeds will be used to advance the Zika and multivalent filovirus (Ebola and Marburg) vaccine programmes.

Emergex Vaccines Approved as Member of the Social Stock Exchange

20th February 2017

Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announces that they have been approved as a member of the Social Stock Exchange, society’s market for impact investing. This follows the ratification of Emergex’s impact report by the Social Stock Exchange’s independent Admissions Panel.

Emergex Vaccines Provides an Update on Agreement with Midatech Pharma

22nd November 2016

Emergex Vaccines Holding Limited (“Emergex”), a biotechnology company pioneering a new approach to T-cell vaccine development in the field of infectious diseases, today announced that it has paid an upfront technology access fee and option payment of £450,000 to Midatech Pharma (AIM: MTPH, NASDAQ: MTP), under the terms of the contract. This follows the licence granted to Emergex from Midatech Pharma, which was announced in January this year.